Virco (now Janssen Diagnostics, Inc.) acquired LAB TRACKER™ HIV in December 2009. Since that time, the Janssen Diagnostics, Inc. team has actively engaged the user community via a series of web-enabled teleconferences to better understand their needs. The input derived from these meetings has been incorporated into AVIGA™ and AVIGA REPORTER™, two new state-of-the-art health information technology products that will better meet the needs of the HIV treatment community now and in the future.
AVIGA™ and AVIGA REPORTER™ were introduced to the US market in the second half of 2011 and Janssen Diagnostics, Inc. is actively engaged in expanding the community of users. Both new products are designed as web-enabled solutions that are ideally suited for being “interoperable” with other information technology systems and provide platforms for sharing epidemiology data from different sites for research and benchmarking.
AVIGA™ and AVIGA REPORTER™ are designed specifically for HIV clinicians to organize, analyze and help evaluate HIV/AIDS patient data in one complete package. Several desirable features of LAB TRACKER™ HIV, including the ability to monitor longitudinal resistance patterns, assess antiretroviral use, and follow common laboratory parameters, are incorporated into AVIGA™ and AVIGA REPORTER™. Both products incorporate a state-of-the-art clinical intelligence function from MicroStrategy®2 which allows users to design and conduct custom queries of their databases from their desktop without the need for outside IT support. As healthcare providers increasingly move toward implementing evidence-based medical practices, the AVIGA™ solutions support the capture and retrieval of needed data to provide quality, performance and accountability measures.
For those who choose to become members of the AVIGA™ user community, a whole range of new insights and opportunities may open across the user community with AVIGA™ analytics and the Software as a Service (SaaS)3 platform. AVIGA™ and AVIGA REPORTER™ track thousands of data points and information for people living with HIV/AIDS, bringing together multiple, disparate sources of information. The investment in AVIGA™ becomes much more than “just” a subscription software package; it connects our users to an exclusive group of HIV/AIDS clinicians and healthcare providers who harness the power of AVIGA™ analytics to seek out information for making timely research or clinical care decisions to support their patients.
Each individual site uses AVIGA™ in different ways to meet the needs of their unique settings and purposes. Those experiences shape the collective wisdom found within the AVIGA™ user community. Some users capitalize on AVIGA™ for its fully functional electronic health record (EHR) attributes, others use it as an adjunctive EHR or interface for capturing data, and still others want only the reporting functions. Collectively through the AVIGA™ user community and in controlled settings, sites have an opportunity to interact with each other, to problem-solve, to communicate how AVIGA™ is used at their site, share best practices, or discover new ways to use the product.
In the future, members of the AVIGA™ user community may choose to participate in data sharing for the purposes of research and for improving quality of care and advancing science. The AVIGA™ user community allows sites to partner (under strict privacy criteria and limitations) with other collaborating sites to examine differences in treatment practices, explore patient trends and answer research questions that could improve treatment in the larger HIV/AIDS community. The collective data potentially tracked within AVIGA™ could result in one of the largest HIV/AIDS cohorts in the world.4
The AVIGA™ user community goes beyond just discussion about HIV/AIDS or product improvements. Past forums used to connect users have focused on issues surrounding the HITECH Act,5 new and different ways to use AVIGA™ and other services Janssen Diagnostics, Inc. can provide that are of value to our users.
Janssen Diagnostics, Inc. incorporates regular feedback from users to continually update, develop and improve upon AVIGA™’s functionalities. The web-enabled subscription platform means that AVIGA™ users have ready access to ongoing improvements and enhancements as soon as they are available.
On February 2nd, 2012, Virco Lab, Inc.
changed its legal name to Janssen Diagnostics, Inc.
Our website is in the process of being updated to
reflect these name changes.